Comparison of the adjuvanticity of two different delivery systems on the induction of humoral and cellular responses to synthetic peptides

Drug Delivery

Volumn 17, Issue 7, 2010, Pages 490-499

  Mata, Elena ^a   Igartua, Manoli ^a   Hernández, Rosa M ^a   Rosas, Jaiver E ^b   Patarroyo, Manuel E ^b   Pedraz, José L ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

Intradermal; Malaria; Microparticles; Montanide; Vaccine

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G2A; MICROSPHERE; MONTANIDE ISA 720; POLYGLACTIN; S3 MALARIAL SHORT SYNTHETIC MODEL PEPTIDE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BAGG ALBINO MOUSE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG RESPONSE; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; DRUG DELIVERY SYSTEMS; EPITOPES; FEMALE; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; INTERFERON-GAMMA; LACTIC ACID; MALARIA VACCINES; MANNITOL; MICE; MICE, INBRED BALB C; OLEIC ACIDS; PEPTIDES; PLASMODIUM FALCIPARUM; POLYGLYCOLIC ACID; TH1 CELLS; TH2 CELLS; VACCINES, SYNTHETIC;

EID: 77956145723     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2010.483254     Document Type: Article

References (51)

1. Aucouturier, J., Dupuis, S., Deville, S., Ascarateil, S., Ganne, V. (2002). Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines. 1:111-118
2. Audran, R., Peter, K., Dannull, J., Men, Y., Scandella, E., Groetrupp, M., Gander, B., Corradin, G., Régine Audran, Katrin Peter, Jens Dannull, Ying Men, Elke Scandella, Marcus Groettrup, Bruno Gander, Giampietro Corradin. (2003). Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine. 21:1250-1255.
3. Babiuk, S., Baca-Estrada, M., Babiuk, L.A., Ewen, C., Foldvari, M. (2000). Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. J Contr Rel. 66:199-214.
4. Benmohamed, L., Tomas, A., Bossus, M., Brahimi, K., Wubben, J., Gras-Masse, H., Druilhe, P. (2000). High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules. Vaccine. 18:2843-2855.
5. Bouharoun-Tayoun, H., Attanath, P., Sabchareon, A., Chongsuphajaisiddhi, T., Druilhe, P. (1990). Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med. 172:1633-1641
6. Bouharoun-Tayoun, H., Druilhe, P. (1992). Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect Immun. 60:1473-1481
7. Brayden, D.J., Templeton, L., McClean, S., Barbour, R., Huang, J., Nguyen, M., Ahern, D., Motter, R., Johnson-Wood, K., Vasquez, N., Schenk, D., Seubert, P. (2001). Encapsulation in biodegradable microparticles enhances serum antibody response to parenterally-delivered b-amyloid in mice. Vaccine. 19:4185-4193
8. Carcaboso, A.M., Hernández, R.M., Igartua, M., Gascón, A.R., Rosas, J.E., Patarroyo, M.E., Pedraz, J.L. (2003). Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66. Int J Pharm. 260:273-282
9. Carcaboso, A.M., Hernández, R.M., Igartua, M., Rosas, J.E., Patarroyo, M.E., Pedraz, J.L. (2004a). Enhancing immunogenic-ity and reducing dose of microparticulated synthetic vaccines: single intradermal administration. Pharm Res. 21:121-126.
10. Carcaboso, A.M., Hernández, R.M., Igartua, M., Rosas, J.E., Patarroyo, M.E., Pedraz J.L. (2004b). Potent, long lasting systemic antibody levels and mixed T1/T2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. Vaccine. 22:1423-1432
11. Clealand, J.L. (1999). Single-administration vaccines: controlled-release technology to mimic repeated immunizations. Trends Biotechnol. 17:25-29
12. Constant, S.L., Bottomly, K. (1997). Induction of T1 and T2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol. 15:297-322.
13. Daubersies, P., Tomas, A.W., Millet, P., Brahimi, K., Langermans, J.A., Ollomo, B., BenMohamed, L., Slierendregt, B., Eling, W., Van Belkum, A., Dubreuil, G., Meis, J.F., Guerin-Marchand, C., Cayphas, S., Cohen, J., Gras-Masse, H., Druilhe, P. (2000). Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat Med. 6:1258-1263
14. Deville, S., Pooter, A., Aucouturier, J., Lainé-Prade, V., Cote, M., Boireau, P., Vallee, I. (2005). Infuence of adjuvant formulation on the induced protection of mice immunized with total soluble antigen of Trichinella spiralis. Vet Parasitol. 132:75-80.
15. Dodoo, D., Teisen, M., Kurtzhals, J.A., Akanmori, B.D., Koram, K.A., Jepsen, S., Nkrumah, F.K., Teander, T.G., Hviid, L. (2000). Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. J Infect Dis. 181:1202-1205
16. Genton, B., Al-Yaman, F., Betuela, I., Anders, R.F., Saul, A., Baea, K., Mellombo, M., Taraika, J., Brown, G.V., Pye, D., Irving, D.O., Felger, I., Beck, H.P., Smith, T.A., Alpers, M.P. (2003). Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine. 22:30-41.
17. Giunchedi, P., Conti, B., Scalia, S., Conte, U. (1998). In vitro degradation study of polyester microspheres by a new HPLC method for monomer release determination. Nature. 56:53-62.
18. Gómez, C.E., Navea, L., Lobaina, L., Dubed, M., Expósito, N., Soto, A., Duarte, C.A. (1999). The V3 loop based multi-epitope polypeptide TAB9 adjuvated with Montanide ISA720 is highly immunogenic in nonhuman primates and induces neutralizing antibodies against fve HIV-1 isolates. Vaccine. 17:2311-2319
19. Gupta, R.K. (1998). Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev. 32:155-172
20. Hermsen, C.C., Verhage, D.F., Telgt, D.S.C., Teelen, K., Bousema, J.T., Roestenberg, M., Bolad, A., Berzins, K., Corradin, G., Leroy, O., Teisen, M., Sauerwein, R.W. (2007). Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. Vaccine. 25:2930-2940
21. Hirabayashi, Y., Tamura, S.I., Suzuki, Y., Nagamine, T., Aizawa, C., Shimada, K., Kurata, T. (1991). H-2-unrestricted adjuvant efect of cholera toxin B subunit on murine antibody responses to infu-enza virus haemagglutinin. Immunology. 72:329-335
22. Igartua, M., Hernández, R.M., Esquisabel, A., Gascón, A.R., Calvo, M.B., Pedraz, J.L. (1998). Stability of BSA encapsulated into PLGA microspheres using PAGE and capillary electrophoresis. Int J Pharm. 169:45-54.
23. Ito, K., Takeuchi, Y., Ito, K., Kato, S. (2000). Strain-dependent antibody response induced by DNA immunization. Immunol Lett. 74:245-250
24. Johansen, P., Men, Y., Hans, P., Merkle, H.P., Gander, B. (2000). Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur J Pharm Biopharm. 50:129-146
25. Lindblad, E.B. (2004). Aluminium adjuvants\in retrospect and prospect. Vaccine. 22:3658-3668
26. + T lymphocyte immune response in humans. Implications for vaccination strategies. Eur J Immunol. 31:1989-1998
27. Marciani, D.J. (2002). Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today. 8:934-943
28. Mata, E., Carcaboso, A.M., Hernández, R.M., Igartua, M., Corradin, G., Pedraz, J.L. (2007). Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice. Vaccine. 25:877-885
29. Men, Y., Tamber, H., Audran, R., Gander, B., Corradin, G. (1997). Induction of a cytotoxic T lymphocyte response by immunization with a Malaria specifc CTL peptide entrapped in biodegradable polymer microspheres. Vaccine. 15:1405-1412
30. Merrifeld, B. (1963). Solid phase peptide synthesis. I. Synthesis of thetrapeptide. J Am Chem Soc. 85:2149-2154
31. Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 65:55-63.
32. Newman, K.D., Elamanchili, P., Kwon, G.S., Samuel, J. (2002). Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J Biomed Mater Res. 60:480-486
33. O'Hagan, D.T. (1998). Microparticles and polymers for the mucosal delivery of vaccines. Adv Drug Deliv Rev. 34:305-320
34. Partidos, C.D., Vohra, P., Jones, D.H., Farrar, G., Steward, M.W. (1999). Induction of cytotoxic T-cell responses following oral immunization with synthetic peptides encapsulated in PLG microparticles. J Contr Rel. 62:325-332
35. Peter, K., Men, Y., Pantaleo, G., Gander, B., Corradin, G. (2001). Induction of a cytotoxic T-cell response to HIV-1 proteins with short synthetic peptides and human compatible adjuvants. Vaccine. 19:4121-4129
36. Puri, N., Weyand, E.H., Abdel-Rahman, S.M., Sinko, P.J. (2000). An investigation of the intradermal route as an efective means of immunization for microparticulate vaccine delivery systems. Vaccine. 18:2600-2612
37. Raya, N.E., Quintana, D., Carrazana, Y., Gomez, C.E., Duarte, C.A. (1999). A prime-boost regime that combines Montanide ISA 720 and Alhydrogel to induce antibodies against the HIV-1 derived multiepitope polypeptide TAB9. Vaccine. 19:2646-2650
38. Richie, T.L., Saul, A. (2002). Progress and challenges for malaria vaccines. Nature. 415:694-701.
39. Rosas, J.E., Hernández, R.M., Gascón, A.R., Igartua, M., Guzman, F., Patarroyo, M.E., Pedraz, J.L. (2001). Biodegradable PLGA micro-spheres as a delivery system for malaria synthetic peptide SPf66. Vaccine. 19:4445-4451
40. Rosas, J.E., Pedraz, J.L., Hernández, R.M., Gascón, A.R., Igartua, M., Guzman, F., Rodríguez, R., Cortés, J., Patarroyo, M.E. (2002). Remarkably high antibody levels and protection against P. falci-parum malaria in Aotus monkeys after a single immunisation of SPf66 encapsulated in PLGA microspheres. Vaccine. 20:1707-1710
41. Salmon, J.K., Armstrong, C.A., Ansel, J.C. (1994). The skin as an immune organ. West J Med. 160:146-152
42. Saul, A., Lawrence, G., Smillie, A., Rzepczyk, C.M., Reed, C., Taylor, D., Anderson, K., Stowers, A., Kemp, R., Allworth, A., Anders, R.F., Brown, G.V., Pye, D., Schoofs, P., Irving, D.O., Dyer, S.L., Woodrow, G.C., Briggs, W.R.S., Reber, R., Stürchler, D. (1999). Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine. 17:3145-3159
43. Smith, P.K., Krohn, R.I., Hermanson, G.T., Mallia, A.K., Gartner, F.H., Provenzano, M.D. (1985). Measurement of protein using bicin-choninic acid. Anal Biochem. 150:85.
44. Snow, R.W., Guerra, C.A., Noor, A.M., Myint, H.Y., Hay, S.I. (2005). The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature. 434:214-217
45. Sugauchi, F., Wang, R.Y., Qiu, Q., Jin, B., Alter, H.J., Shih, J.W. (2006). Vigorous hepatitis C virus-specifc CD4+ and CD8+ T cell responses induced by protein immunization in the presence of Montanide ISA720 plus synthetic oligodeoxynucleotides containing immunostimulatory cytosine-guanine dinucleotide motifs. J Infect Dis. 193:563-572
46. Toapanta, F.R., Ross, T.M. (2004). Mouse strain-dependent difer-ences in enhancement of immune responses by C3d. Vaccine. 22:1773-1781
47. Toledo, H., Baly, A., Castro, O., Resik, S., Laferté, J., Rolo, F., Navea, L., Lobaina, L., Cruz, O., Míguez, J., Serrano, T., Sierra, B., Pérez, L., Ricardo, M.E., Dubed, M., Lubián, A.L., Blanco, M., Millán, J.C., Ortega, A., Iglesias, E., Pentón, E., Martín, Z., Pérez, J., Díaz, M., Duarte, C.A. (2001). A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers. Vaccine. 19:4328-4336
48. van de Weert, M., Hennink, W.E., Jiskoot, W. (2000). Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res. 17:1159-1167
49. World Health Organization. (2008). WHO report on infectious diseases. Removing obstacles to healthy development. Geneva: World Health Organization. WHO/CDS/99.1. Available online at: http://www.who.int/infectious-disease-report/ pages/graph1. html, Accessed November 2009.
50. Yazdani, S.S., Shakri, A.R., Mukherjee, P., Baniwal, S.K., Chitnis, C.E. (2004). Evaluation of immune responses elicited in mice against a recombinant malaria vaccine based on Plasmodium vivax Dufy binding protein. Vaccine. 22:3727-3737
51. Zauner, W., Lingnau, K., Mattner, F., von Gabain, A., Buschle, M. (2001). Defned synthetic vaccines. Biol Chem. 382:585-591